307 related articles for article (PubMed ID: 22689925)
1. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI.
Viel T; Talasila KM; Monfared P; Wang J; Jikeli JF; Waerzeggers Y; Neumaier B; Backes H; Brekka N; Thorsen F; Stieber D; Niclou SP; Winkeler A; Tavitian B; Hoehn M; Bjerkvig R; Miletic H; Jacobs AH
J Nucl Med; 2012 Jul; 53(7):1135-45. PubMed ID: 22689925
[TBL] [Abstract][Full Text] [Related]
2. Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI.
Viel T; Boehm-Sturm P; Rapic S; Monfared P; Neumaier B; Hoehn M; Jacobs AH
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1595-606. PubMed ID: 23754761
[TBL] [Abstract][Full Text] [Related]
3. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.
Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH
Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
[TBL] [Abstract][Full Text] [Related]
5. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
6. [
Hovhannisyan N; Fillesoye F; Guillouet S; Ibazizene M; Toutain J; Gourand F; Valable S; Plancoulaine B; Barré L
Theranostics; 2018; 8(16):4563-4573. PubMed ID: 30214639
[TBL] [Abstract][Full Text] [Related]
7. Multimodal imaging based on MRI and PET reveals [(18)F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma.
Corroyer-Dulmont A; Pérès EA; Gérault AN; Savina A; Bouquet F; Divoux D; Toutain J; Ibazizène M; MacKenzie ET; Barré L; Bernaudin M; Petit E; Valable S
Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):682-94. PubMed ID: 26537287
[TBL] [Abstract][Full Text] [Related]
8. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
9. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
Prieto E; Martí-Climent JM; Domínguez-Prado I; Garrastachu P; Díez-Valle R; Tejada S; Aristu JJ; Peñuelas I; Arbizu J
J Nucl Med; 2011 Jun; 52(6):865-72. PubMed ID: 21571807
[TBL] [Abstract][Full Text] [Related]
10. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
11. In vivo imaging of cell proliferation enables the detection of the extent of experimental rheumatoid arthritis by 3'-deoxy-3'-18f-fluorothymidine and small-animal PET.
Fuchs K; Kohlhofer U; Quintanilla-Martinez L; Lamparter D; Kötter I; Reischl G; Röcken M; Pichler BJ; Kneilling M
J Nucl Med; 2013 Jan; 54(1):151-8. PubMed ID: 23213198
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
[TBL] [Abstract][Full Text] [Related]
13. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ
J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800
[TBL] [Abstract][Full Text] [Related]
14. Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-¹⁸F-Fluorothymidine PET and Diffusion-Weighted MR Imaging.
Schelhaas S; Wachsmuth L; Viel T; Honess DJ; Heinzmann K; Smith DM; Hermann S; Wagner S; Kuhlmann MT; Müller-Tidow C; Kopka K; Schober O; Schäfers M; Schneider R; Aboagye EO; Griffiths J; Faber C; Jacobs AH
J Nucl Med; 2014 Jun; 55(6):983-8. PubMed ID: 24777288
[TBL] [Abstract][Full Text] [Related]
15. Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma.
Nedergaard MK; Michaelsen SR; Perryman L; Erler J; Poulsen HS; Stockhausen MT; Lassen U; Kjaer A
Nucl Med Biol; 2016 Mar; 43(3):198-205. PubMed ID: 26924500
[TBL] [Abstract][Full Text] [Related]
16. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
17. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer.
Wang H; Zhang J; Tian J; Qu B; Li T; Chen Y; Liu J; Wang S
J Nucl Med; 2009 Nov; 50(11):1857-64. PubMed ID: 19837754
[TBL] [Abstract][Full Text] [Related]
18. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET.
Waldherr C; Mellinghoff IK; Tran C; Halpern BS; Rozengurt N; Safaei A; Weber WA; Stout D; Satyamurthy N; Barrio J; Phelps ME; Silverman DH; Sawyers CL; Czernin J
J Nucl Med; 2005 Jan; 46(1):114-20. PubMed ID: 15632041
[TBL] [Abstract][Full Text] [Related]
19. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
[TBL] [Abstract][Full Text] [Related]
20. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog.
Shibahara I; Kumabe T; Kanamori M; Saito R; Sonoda Y; Watanabe M; Iwata R; Higano S; Takanami K; Takai Y; Tominaga T
J Neurosurg; 2010 Aug; 113(2):358-68. PubMed ID: 19895196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
